CHP
JAZZ icon

Cable Hill Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Cable Hill Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-59
Closed -$11K – 732
2015
Q2 		$11K Hold
59
– – 0.01% 422
2015
Q1 		$10K Hold
59
– – 0.01% 433
2014
Q4 		$10K Buy
+59
New +$9.79K 0.01% 428

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Cable Hill Partners's JAZZ Position: Q3 2015 in Review

Cable Hill Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2015, closing a stake of 59 shares — an estimated $11K sold.

Cable Hill Partners first reported a position in JAZZ in Q4 2014 and held it in 3 quarters. The position peaked at $11K in Q2 2015. 360 funds tracked by Wall St. Rank hold JAZZ as of Q3 2015.

  • Cable Hill Partners reported no remaining Jazz Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Cable Hill Partners sold 59 Jazz Pharmaceuticals shares in Q3 2015, an estimated $11K.
  • Cable Hill Partners first reported a position in Jazz Pharmaceuticals in Q4 2014 and held it in 3 quarters.
  • Cable Hill Partners's Jazz Pharmaceuticals position peaked at $11K in Q2 2015.
  • 360 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2015.

Based on Cable Hill Partners's 13F filing for Q3 2015, filed 4 Aug 2016.